Incyte Corporation $INCY Stock: Fisher Asset Management LLC Increases Stake

Fisher Asset Management LLC increased its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 6.1% in the third quarter, HoldingsChannel.com reports. The fund owned 145,442 shares of the biopharmaceutical company’s stock after acquiring an additional 8,424 shares during the period. Fisher Asset Management LLC’s holdings in Incyte were worth $17,649,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. Greenleaf Trust boosted its holdings in Incyte by 2.8% in the second quarter. Greenleaf Trust now owns 3,358 shares of the biopharmaceutical company’s stock valued at $381,000 after acquiring an additional 93 shares in the last quarter. Parallel Advisors LLC raised its holdings in Incyte by 2.4% in the 3rd quarter. Parallel Advisors LLC now owns 5,082 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 121 shares in the last quarter. Mather Group LLC. raised its holdings in Incyte by 13.5% in the 3rd quarter. Mather Group LLC. now owns 1,157 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 138 shares in the last quarter. Tema ETFs LLC raised its holdings in Incyte by 5.7% in the 2nd quarter. Tema ETFs LLC now owns 2,704 shares of the biopharmaceutical company’s stock worth $307,000 after purchasing an additional 145 shares in the last quarter. Finally, Trust Point Inc. lifted its position in shares of Incyte by 5.5% in the 2nd quarter. Trust Point Inc. now owns 2,968 shares of the biopharmaceutical company’s stock worth $336,000 after purchasing an additional 156 shares during the period. Institutional investors own 96.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on INCY shares. BMO Capital Markets reaffirmed a “market perform” rating on shares of Incyte in a research note on Tuesday, October 27th. Piper Sandler increased their price target on shares of Incyte from $110.00 to $130.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. Morgan Stanley started coverage on shares of Incyte in a research note on Tuesday, October 20th. They issued an “equal weight” rating and a $119.00 price target for the company. HC Wainwright restated a “buy” rating on shares of Incyte in a report on Tuesday, October 27th. Finally, Stifel Nicolaus lifted their price objective on Incyte from $145.00 to $157.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Eleven analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $132.86.

View Our Latest Research Report on Incyte

Incyte Price Performance

Shares of INCY stock opened at $120.97 on Monday. The business’s fifty day moving average is $119.18 and its 200 day moving average is $108.96. The stock has a market cap of $24.66 billion, a price-to-earnings ratio of 64.35, a PEG ratio of 4.40 and a beta of 0.78. Incyte Corporation has a twelve month low of $89.25 and a twelve month high of $132.60.

Incyte (NASDAQ:INCY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, beating the consensus estimate of ($3.93) by $0.33. The business had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.46 billion. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The company’s revenue for the quarter was up 14.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.26 earnings per share. Equities research analysts expect that Incyte Corporation will post 2.24 earnings per share for the current fiscal year.

Insider Transactions at Incyte

In other news, insider Pablo Cagnoni sold 2,642 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $112.71, for a total value of $297,779.82. Following the sale, the insider directly owned 183,200 shares of the company’s stock, valued at $20,648,472. This represents a 1.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas Tray sold 610 shares of the stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $118.96, for a total transaction of $72,565.60. Following the completion of the transaction, the insider owned 21,126 shares of the company’s stock, valued at approximately $2,513,148.96. The trade was a 2.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 254,246 shares of company stock valued at $30,162,968 in the last three months. 16.20% of the stock is currently owned by company insiders.

Incyte Company Profile

(Free Report)

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.

Read More

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY – Free Report).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.